Health
First in Human Study with Novel Antisense Oligonucleotide – EurekAlert
A single intravenous dose of MRG-110, an anti-microRNA drug, significantly reduced miR-92a levels in the blood of healthy humans.
IMAGE: focuses on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression.
view more
Credit: Mary Ann Liebert, Inc., publishers
New Rochelle, NY, August 11, 2020–A single intravenous dose of MRG-110, an anti-microRNA drug, significantly reduced miR-92a levels in the blood of healthy humans. Inhibition of miR-92a has shown beneficial effects in animal models, including improved vascularization after myocar…
-
General21 hours agoSearch underway for missing boat off South Australia’s Cape Jaffa
-
Noosa News22 hours agoQueensland coroner investigates ‘extremely unusual’ deaths of premature twin boys
-
Noosa News23 hours agoChristmas tragedy: NSW woman dies after alleged deliberate hit-and-run on Sunshine Coast
-
Noosa News24 hours agoWooloowin crash causes Airport, Doomben and Shorncliffe line suspensions